stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
121.73
2.60
+2.18%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Free cash flow margin
GRAIL, Inc.'s free cash flow margin over the twelve months to 30 September 2026 was −187.3%, up 16.5 percentage points from fiscal 2025 (−203.8%). That is below the Diagnostics & Research industry median of 0.00% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −203.8% | 259.89 |
| FY2024 | −463.7% | 190.08 |
| FY2023 | −653.8% | 397.85 |
| FY2022 | −1,051.6% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| VCYT Veracyte, Inc. compare | 27.8% |
| QGEN QIAGEN N.V. compare | 21.0% |
| CDNA CareDx, Inc. compare | 12.0% |
| SHC Sotera Health Company compare | 11.0% |
| ICLR ICON PLC compare | 10.4% |
| BLLN BillionToOne, Inc. compare | 7.76% |
| RDNT RadNet, Inc. compare | 3.28% |
| ADPT Adaptive Biotechnologies Corporation compare | −2.96% |
| GRAL GRAIL, Inc. | −187.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement